These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 16764068)

  • 1. Therapeutic options for treatment experienced patients: a focus on resistance testing and optimizing background therapy.
    Sax PE
    AIDS Read; 2006 May; 16(5):265-75, 277-8. PubMed ID: 16764068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of antiretroviral resistance on response in treatment-experienced patients.
    Kuritzkes DR
    AIDS Read; 2003 Dec; 13(12 Suppl Antiretroviral):S5-11. PubMed ID: 19967805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial comment: treating the experienced patient--when and how to use new agents.
    Gallant JE
    AIDS Read; 2006 May; 16(5):274-5. PubMed ID: 16764069
    [No Abstract]   [Full Text] [Related]  

  • 4. Antiretroviral regimens for treatment-experienced patients with HIV-1 infection.
    Lagnese M; Daar ES
    Expert Opin Pharmacother; 2008 Apr; 9(5):687-700. PubMed ID: 18345948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations.
    Wilson LE; Gallant JE
    Clin Infect Dis; 2009 Jan; 48(2):214-21. PubMed ID: 19072245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individualized therapy for the treatment-experienced patient.
    Walmsley S
    AIDS Read; 2003 Jun; 13(6 Suppl):S11-5. PubMed ID: 12838742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current management challenges in HIV: antiretroviral resistance.
    Kuritzkes DR; Boyle BA; Gallant JE; Squires KE; Zolopa A
    AIDS Read; 2003 Mar; 13(3):133-5, 138-42. PubMed ID: 12728868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of heavily antiretroviral-experienced HIV-infected patients.
    Lunzen Jv
    AIDS Rev; 2007; 9(4):246-53. PubMed ID: 18219368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of patients with virologic and metabolic failure.
    Kuritzkes DR
    AIDS Read; 2003 Jun; 13(6 Suppl):S17-22. PubMed ID: 12838743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current concepts in antiretroviral therapy failure.
    del Rio C
    Top HIV Med; 2006; 14(3):102-6. PubMed ID: 16946454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why do patients fail HIV therapy?
    Waters L; Nelson M
    Int J Clin Pract; 2007 Jun; 61(6):983-90. PubMed ID: 17504360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virologic suppression in treatment-experienced patients after virologic rebound or failure of therapy.
    Sarmento-Castro R; Vasconcelos C; Aguas MJ; Marques R; Oliveira J
    Curr Opin HIV AIDS; 2011 Dec; 6 Suppl 1():S12-20. PubMed ID: 22156775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chumpathat N; Chantratita W
    Clin Infect Dis; 2007 Feb; 44(3):447-52. PubMed ID: 17205457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of resistance to antiretroviral therapy in the minority community.
    Rodriguez AE; Campo RE; Gathe JC; Kwakwa HA
    AIDS Read; 2004 Oct; 14(10 Suppl):S9-11. PubMed ID: 15497217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen.
    Hatano H; Hunt P; Weidler J; Coakley E; Hoh R; Liegler T; Martin JN; Deeks SG
    Clin Infect Dis; 2006 Nov; 43(10):1329-36. PubMed ID: 17051502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Third line anti-HIV therapy options.
    Proj Inf Perspect; 2004 Jan; (37):19-21. PubMed ID: 15119286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raltegravir: the first HIV integrase inhibitor.
    Cocohoba J; Dong BJ
    Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs.
    Perno CF; Moyle G; Tsoukas C; Ratanasuwan W; Gatell J; Schechter M
    J Med Virol; 2008 Apr; 80(4):565-76. PubMed ID: 18297706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.